Dr. Gregory Bell was appointed Monitor by the FTC in several healthcare transactions to monitor Respondents’ compliance with post-merger divestiture obligations and other related requirements of the agreement. Dr. Bell and the CRA team complied with all monitor obligations, including conducting weekly and bi-weekly calls with the respective parties, and submitting a monthly report to the FTC on activities, issues, and opinions related to the divestiture obligations.
CRA's RADAR Insights: Factors impacting GKV rebates for orphan drugs in Germany - Part 1
Germany’s AMNOG introduced in 2011 follows health technology assessments (HTAs) with reimbursement price negotiations and some exceptions for orphan drugs...